BioCentury

INTRODUCTION

Letter from the Editor

PART 1

Imperative of COVID

PART 2

Addressing disparities

PART 3

Data sharing

PART 4

Master protocols

PART 5

Pandemic preparedness

ARTICLE | Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

COVID-19 has lit a path to greater data sharing

By C. Simone fishburn, editor in chief, and Steve Usdin, Washington Editor  
September 10, 2020 1:15 AM UTC

This is the third article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. 

Biopharma companies have come together to share data in COVID-19 because they believe that getting data out fast and wide is the best way to expedite development. ...

BCIQ Company Profiles

Critical Path Institute

TransCelerate BioPharma Inc.

Vivli